Atossa Therapeutics appoints Jonathan Finn to board of directors and audit committee

ATOSSA THERAPEUTICS, INC.

Jonathan Finn appointed to board as Class I director and audit committee member, effective November 9, 2023.
Finn succeeds Greg Weaver and will serve until the 2025 Annual Meeting of Stockholders.
Finn brings over 25 years of financial industry experience, focusing on early to mid-stage biotech and tech companies.
Compensation follows standard non-employee director terms as per 2023 proxy; standard indemnification agreement to be entered.
No arrangements, family relationships, or material interests in any transactions requiring disclosure.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jonathan Finn

Class I Director

ATOS · ATOSSA THERAPEUTICS, INC.

Effective: 2023-11-09
Filed: November 9, 2023, 6:59 PM ET

Jonathan Finn, CFA, has been appointed to the Company's board of directors, effective immediately.

Departed

Greg Weaver

Class I Director

ATOS · ATOSSA THERAPEUTICS, INC.

Effective: 2023-11-09
Successor: Jonathan Finn
Filed: November 9, 2023, 6:59 PM ET

Mr. Finn succeeded Greg Weaver as a Class I director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jonathan Finn was appointed as Class I Director at ATOSSA THERAPEUTICS, INC..

Action: appointed
Role: Class I Director

Exact text from the filing

Jonathan Finn, CFA, has been appointed to the Company's board of directors, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Greg Weaver departed as Class I Director at ATOSSA THERAPEUTICS, INC..

Action: succeeded
Role: Class I Director

Exact text from the filing

Mr. Finn succeeded Greg Weaver as a Class I director

View on SEC.gov

ATOSSA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-031085

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.